Earn rewards for your opinion on lab products.

Get exclusive insights into life science trends.

Stay up to date on research news.

COVID-19 mRNA-based vaccines benefit from decades of research
May 25, 2022 -- 25 years ago Dr. Drew Weissman, PhD, an infectious disease expert at Penn Medicine, and RNA biologist Kati Kariko, PhD, began their collaboration in what would become a critical technology used in some of today’s COVID-19 mRNA-based vaccines. Weissman spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC about their research journey. Read More
Next-generation AAV capsids hold key to developing life-changing therapies
May 24, 2022 -- Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional adeno-associated virus (AAV) serotypes in non-human primates, according to Todd Carter, PhD, senior vice president for research. The company presented data on the platform at the American Society of Gene & Cell Therapy 2022 annual meeting. Read More
Genenta Science reports preliminary results of Temferon-glioblastoma study
May 24, 2022 -- Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD. ScienceBoard.net spoke to Gentner at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC, about Temferon. Read More
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
May 23, 2022 -- In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview of the company's development of novel treatments for inherited forms of blindness at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
How to address challenges in producing AAV vectors
May 23, 2022 -- There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors, contends Ines do Carmo Gil-Goncalves, PhD, head of vector production for Cevec Pharmaceuticals GmbH. Gil-Goncalves discussed how Cevec’s Elevecta platform can help overcome these challenges at the American Society of Gene & Cell Therapy 2022 annual meeting. Read More
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
May 20, 2022 -- Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation, according to Thomas McCauley, PhD, chief scientific officer. McCauley spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC. Read More
Delivery of gene therapies remains a key challenge
May 19, 2022 -- Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge, contends Kevin Foust, PhD, senior vice president for preclinical and translational medicine at Jaguar Gene Therapy. Foust spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC. Read More
Next evolution of CAR T-cell therapy is solid tumors
May 18, 2022 -- While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the technology is solid tumors, said Sangamo CEO Sandy Macrae, PhD, at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
11.7T MR spectroscopy quantifies brain glucose metabolism
May 17, 2022 -- French researchers have developed a new MR (magnetic resonance) spectroscopy approach to study brain glucose metabolism, a process significantly involved in Alzheimer's disease. They presented their work in an animal study at the annual meeting of the International Society for Magnetic Resonance in Medicine. Read More
Sample management, characterization is a growing challenge in CGT
May 16, 2022 -- From academic research centers to small biotechs to large pharmaceutical companies, the numbers of biosamples and measurements are growing exponentially in the field of cell and gene therapy (CGT). Andrea O'Hara and David Lewandowski of Azenta Life Sciences, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting about the challenge of sample management and characterization. Read More
Autologous cell therapy has its limitations, risks
May 16, 2022 -- Cell-based therapies generated using a patient's own cells, called autologous cell therapy, have their own inherent risks and limitations, contends Roman Vincent, senior global director of strategic marketing at MaxCyte. Vincent spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting in San Francisco. Read More
What's needed for cell and gene therapies to become the new standard of care?
May 13, 2022 -- Cell and gene therapies (CGTs) have the potential to be the new standard of care. Delara Motlagh, PhD, general manager at Terumo Blood and Cell Technologies, told ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting that increasing access to CGTs is critical to making that a reality. Read More
Automation, standardization hold potential for overcoming CGT manufacturing challenges
May 12, 2022 -- Challenges in cell and gene therapy (CGT) manufacturing can be overcome by fully automating and standardizing the process, contends David Smith, vice president of technical operations at Ori Biotech. Smith spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting about Ori Biotech's new digital platform that closes, automates, and standardizes CGT manufacturing. Read More
CGT ecosystem is only way to accelerate development for more patients: Autolomous COO
May 12, 2022 -- Digital solutions provider Autolomous specializes in building solutions for the cell and gene therapy (CGT) industry with an emphasis on collaborative partnerships with suppliers across the value chain. Kwok Pang, the company’s chief operating officer (COO), spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy 2022 annual meeting in San Francisco. Read More
Galipeau to replace Levine as ISCT president
May 11, 2022 -- Dr. Jacques Galipeau, associate dean for therapeutics development at the University of Wisconsin-Madison, is set to replace Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, as the next president (2022-2024) of the International Society for Cell & Gene Therapy (ISCT). Read More
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter
Latest Tweets